Childhood acute myeloid leukaemia

被引：68

作者：

Rubnitz, Jeffrey E. ^{[1
,2
]}

Inaba, Hiroto ^{[1
,2
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA

[2] Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Paediat, Memphis, TN 38163 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 159卷 / 03期

基金：

美国国家卫生研究院;

关键词：

acute myeloid leukaemia; AML; childhood leukaemia; ACUTE MYELOGENOUS LEUKEMIA; STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; HIGH-DOSE CYTARABINE; BONE-MARROW-TRANSPLANTATION; COLONY-STIMULATING FACTOR; AGENT ARSENIC TRIOXIDE; NATURAL-KILLER-CELLS; ACUTE MYELOBLASTIC-LEUKEMIA; CHILDRENS-ONCOLOGY-GROUP;

D O I：

10.1111/bjh.12040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although acute myeloid leukaemia (AML) has long been recognized for its morphological and cytogenetic heterogeneity, recent high-resolution genomic profiling has demonstrated a complexity even greater than previously imagined. This complexity can be seen in the number and diversity of genetic alterations, epigenetic modifications, and characteristics of the leukaemic stem cells. The broad range of abnormalities across different AML subtypes suggests that improvements in clinical outcome will require the development of targeted therapies for each subtype of disease and the design of novel clinical trials to test these strategies. It is highly unlikely that further gains in long-term survival rates will be possible by mere intensification of conventional chemotherapy. In this review, we summarize recent studies that provide new insight into the genetics and biology of AML, discuss risk stratification and therapy for this disease, and profile some of the therapeutic agents currently under investigation.

引用

页码：259 / 276

页数：18

共 174 条

[1] Improved outcome after relapse in children with acute myeloid leukaemia [J].

Abrahamsson, Jonas ;

Clausen, Niels ;

Gustafsson, Goran ;

Hovi, Liisa ;

Jonmundsson, Gudmundur ;

Zeller, Bernward ;

Forestier, Erik ;

Heldrup, Jesper ;

Hasle, Henrik .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (02) :229-236

[2] Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate [J].

Abrahamsson, Jonas ;

Forestier, Erik ;

Heldrup, Jesper ;

Jahnukainen, Kirsi ;

Jonsson, Olafur G. ;

Lausen, Birgitte ;

Palle, Josefine ;

Zeller, Bernward ;

Hasle, Henrik .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) :310-315

[3] Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology [J].

Aladjidi, N ;

Auvrignon, A ;

Leblanc, T ;

Perel, Y ;

Bénard, A ;

Bordigoni, P ;

Gandemer, V ;

Thuret, I ;

Dalle, JH ;

Piguet, C ;

Pautard, B ;

Baruchel, A ;

Leverger, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4377-4385

[4] Prevention of bacterial infection in pediatric oncology: What do we know, what can we learn? [J].

Alexander, Sarah ;

Nieder, Michael ;

Zerr, Danielle M. ;

Fisher, Brian T. ;

Dvorak, Christopher C. ;

Sung, Lillian .

PEDIATRIC BLOOD & CANCER, 2012, 59 (01) :16-20

[5] IDH1 and IDH2 mutations in pediatric acute leukemia [J].

Andersson, A. K. ;

Miller, D. W. ;

Lynch, J. A. ;

Lemoff, A. S. ;

Cai, Z. ;

Pounds, S. B. ;

Radtke, I. ;

Yan, B. ;

Schuetz, J. D. ;

Rubnitz, J. E. ;

Ribeiro, R. C. ;

Raimondi, S. C. ;

Zhang, J. ;

Mullighan, C. G. ;

Shurtleff, S. A. ;

Schulman, B. A. ;

Downing, J. R. .

LEUKEMIA, 2011, 25 (10) :1570-1577

[6] Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia [J].

Arceci, RJ ;

Sande, J ;

Lange, B ;

Shannon, K ;

Franklin, J ;

Hutchinson, R ;

Vik, TA ;

Flowers, D ;

Aplenc, R ;

Berger, MS ;

Sherman, ML ;

Smith, FO ;

Bernstein, I ;

Sievers, EL .

BLOOD, 2005, 106 (04) :1183-1188

[7] High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine [J].

Bachas, Costa ;

Schuurhuis, Gerrit Jan ;

Hollink, Iris H. I. M. ;

Kwidama, Zinia J. ;

Goemans, Bianca F. ;

Zwaan, C. Michel ;

van den Heuvel-Eibrink, Marry M. ;

de Bont, Eveline S. J. M. ;

Reinhardt, Dirk ;

Creutzig, Ursula ;

de Haas, Valerie ;

Assaraf, Yehuda G. ;

Kaspers, Gertjan J. L. ;

Cloos, Jacqueline .

BLOOD, 2010, 116 (15) :2752-2758

[8] The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia [J].

Balgobind, B. V. ;

Zwaan, C. M. ;

Pieters, R. ;

Van den Heuvel-Eibrink, M. M. .

LEUKEMIA, 2011, 25 (08) :1239-1248

[9] Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study [J].

Balgobind, Brian V. ;

Raimondi, Susana C. ;

Harbott, Jochen ;

Zimmermann, Martin ;

Alonzo, Todd A. ;

Auvrignon, Anne ;

Beverloo, H. Berna ;

Chang, Myron ;

Creutzig, Ursula ;

Dworzak, Michael N. ;

Forestier, Erik ;

Gibson, Brenda ;

Hasle, Henrik ;

Harrison, Christine J. ;

Heerema, Nyla A. ;

Kaspers, Gertjan J. L. ;

Leszl, Anna ;

Litvinko, Nathalia ;

Lo Nigro, Luca ;

Morimoto, Akira ;

Perot, Christine ;

Pieters, Rob ;

Reinhardt, Dirk ;

Rubnitz, Jeffrey E. ;

Smith, Franklin O. ;

Stary, Jan ;

Stasevich, Irina ;

Strehl, Sabine ;

Taga, Takashi ;

Tomizawa, Daisuke ;

Webb, David ;

Zemanova, Zuzana ;

Zwaan, C. Michel ;

van den Heuvel-Eibrink, Marry M. .

BLOOD, 2009, 114 (12) :2489-2496

[10] Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group [J].

Bally, Cecile ;

Fadlallah, Jehane ;

Leverger, Guy ;

Bertrand, Yves ;

Robert, Alain ;

Baruchel, Andre ;

Guerci, Agnes ;

Recher, Christian ;

Raffoux, Emmanuel ;

Thomas, Xavier ;

Leblanc, Thierry ;

Idres, Nadia ;

Cassinat, Bruno ;

Vey, Norbert ;

Chomienne, Christine ;

Dombret, Herve ;

Sanz, Miguel ;

Fenaux, Pierre ;

Ades, Lionel .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1641-1646

← 1 2 3 4 5 6 7 8 9 10 →